Heterodimeric antibodies that bind CD3 and tumor antigens
US11225528B2 · kind B2 · utility
7Cited by
126References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 14, 2019 |
| Grant date | Jan 18, 2022 |
| Priority date | — |
| Expiry date | Aug 2, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to novel heterodimeric antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.